Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura

Abstract

Systemic lupus erythematosus (SLE) has been described as a cause of microangiopathic haemolytic anaemia (MAHA), however there is little literature to support this assertion. We report on three patients presenting with SLE and MAHA with a clinical picture indistinguishable from thrombotic thrombocytopenic purpura (TTP), who had underlying lupus nephritis. They all had significant proteinuria and normal Von Willebrand Factor cleaving protease (vWF-CP) levels. Their MAHA fitted better for haemolytic syndrome (HUS) and their cerebral signs were explained either by malignant hypertension or cerebral lupus. Their MAHA only improved when the appropriate treatment for lupus nephritis was given.

We propose that the previously described association between SLE and MAHA, in actuality relates to the underlying presence of lupus nephritis causing haemolytic uraemic syndrome, not TTP. Significant proteinuria was present in all cases of MAHA due to lupus nephritis, so may be a useful discriminatory sign. Furthermore the demonstration of a normal vWF-CP assay aided in the distinction between TTP and MAHA due to lupus nephritis. All our patients responded to mycophenolate mofetil suggesting this may be useful in other cases of lupus nephritis causing HUS. Lupus (2007) 16, 358—362.

Keywords

lupus thrombotic thrombocytopenic purpura

Get full access to this article

View all access options for this article.

References

Levine S. , Shearn MA Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Arch Intern Med 1964; 113: 826—836.

Tsai HM , Lian EC Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 ; 339: 1585—1594.

Fujikawa K. , Suzuki H. , McMullen B. , Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662—1666.

Gerritsen HE , Robles R. , Lammle B. , Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 1654—1661.

Furlan M. , Robles R. , Galbusera M. et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578—1584.

Levy GG , Nichols WC , Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488—494.

Vaidya S. , Abul-ezz S. , Lipsmeyer E. Thrombotic thrombocytopenic purpura and Systemic lupus erythematosis . Scand J Rheumatol 2001; 30: 308—310.

Gatenby PA , Smith H. , Kirwan P. , Lauer CS Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: A case report and review of relationship. J Rheumatol 1981; 8: 504—508.

Blake JS , Butani L. Rapidly progressive lupus glomerulonephritis and concomitant microangiopathy in an adolescent. Lupus 2002; 11: 533—535.

10.

Hamasaki K. , Mimura T. , Kanda H. et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol 2003; 22: 355—358.

11.

Sakarcan A. , Stallworth J. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case and review. Pediatr Nephrol 2001; 16: 672—674.

12.

Hunt L. , Xiaoning Li , Judith James et al. Thrombotic thrombocytopenic purpura (TTP) and systemic lupus erythematosus (SLE): distinct but potentially overlapping syndromes. Blood 2004; 104: 245a.

13.

Pereira A. , Mazzara R. , Monteagudo J. et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange . Ann Hematol 1995; 70: 319—323.

14.

Rock G. , Kelton JG , Shumak KH , Buskard NA , Sutton DM , Benny WB Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Br J Haematol 1998; 103: 1031—1036.

15.

Rock GA , Shumak KH , Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393—397.

16.

Akaogi J. , Akasaka N. , Yamada H. , Hama N. , Satoh M. , Nichols C. , Ozaki S. Intravenous cyclophosphamide therapy in a case with refractory thrombotic microangiopathic hemolytic anemia and SLE. Clin Rheumatol 2004; 23: 541—543.

17.

Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156—1162.

18.

Briggs WA , Choi MJ , Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213—217.

19.

Glicklich D. , Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32: 318—322.

20.

Dooley MA , Cosio FG , Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations . J Am Soc Nephrol 1999; 10: 833—839.